Novel targeted therapies for R/R MF: PIM1 kinase inhibition

During the MPN Hub Steering Committee meeting, Francesco Passamonti, Università degli Studi di Milano, Milan, IT, chaired a discussion on novel targeted therapies for relapsed/refractory (R/R) myelofibrosis (MF), with a focus on PIM1 kinase inhibition. This discussion also featured Tiziano Barbui, Haifa Kathrin Al-Ali, Steffen Koschmieder, Jean-Jacques Kiladjian, Aaron Gerds, and Laura Michaelis.

Passamonti provides an overview of the mechanism of action of PIM1 kinase inhibitors. He then discusses results from a phase I/II trial of nuvisertib, a first-in-class selective PIM1 kinase inhibitor, in patients with R/R MF.

This educational resource is independently supported by Sumitomo Pharma. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. 

Hosted on Acast. See acast.com/privacy for more information.